Brief: Corline Biomedical: Results Of First Study Of Drug Candidate Renaparin
June 10 (Reuters) - Corline Biomedical AB CLBIO.ST :
* DRUG CANDIDATE RENAPARIN SHOWS GOOD SAFETY PROFILE IN
FIRST
STUDY ON PATIENTS
* RENAPARIN HAS GOOD RESULTS FOR BOTH PRIMARY AND SECONDARY
PHASE
1 ENDPOINTS
* NEXT STEP IN DEVELOPMENT OF RENAPARIN EXPECTED TO BE
COMMUNICATED IN SEPTEMBER 2020
Source text for Eikon: ID:nGNECKL0G
Further company coverage: CLBIO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Corline Biomedical AB
See all newsBrief: Corline Biomedical Expectes Positive EBITDA In 2027
Brief: Corline Biomedical: Canada To Grant Kardium Up To C$31.25 Mln For Manufacturing Capacity Expansion
Brief: Corline Biomedical Q2 Net Sales Amount To SEK 4.7 Million
Brief: Corline Biomedical Partner Kardium Receives Approval For Globe Pulsed Field System In Canada
Brief: Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln